The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)
暂无分享,去创建一个
C. Bueno | M. Camós | P. Romecín | J. Dapena | S. Chulián | J. L. Fuster | J. Parras | Albert Manzano-Muñoz | Gloria Hidalgo-Gómez | Santiago Zazo | Yurena Aguilar | Nerea Vega-García | Pablo Velasco | Francisco Bautista | Alba Rubio | Susana Rives | Antonio Pérez | Manuel Ramirez | Cristina Saiz-Ladera | Elisa Izquierdo | Adela Escudero | Margarita Ortega | Carlos Palacio | Pablo Menéndez | Joan Montero | Federico Alvarez | Carmen Ortega-Sabater | María Rosa | Davide Cirillo | Elena García | Jorge García | Alfredo Minguela | Alfredo Minguela | Manuel Ramírez
[1] A. Trifa,et al. Addressing the unmet need for a comprehensive lung cancer registry in Romania , 2023, Frontiers in Oncology.
[2] A. Letai,et al. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia , 2023, Blood advances.
[3] A. Borkhardt,et al. Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants , 2022, Leukemia.
[4] J. Samitier,et al. MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia , 2021, Frontiers in Cell and Developmental Biology.
[5] David C. Jones,et al. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets , 2021, Cancer discovery.
[6] T. Révész,et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. , 2021, European journal of cancer.
[7] S. Rives,et al. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia , 2021, Clinical and Translational Oncology.
[8] D. Steinemann,et al. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome , 2021, Leukemia.
[9] S. Rives,et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) , 2020, British journal of haematology.
[10] S. Rives,et al. ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain , 2019, Clinical and Translational Oncology.
[11] Julian M. Hess,et al. Passenger Hotspot Mutations in Cancer , 2019, bioRxiv.
[12] M. Norkin,et al. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. , 2019, Blood advances.
[13] S. Rives,et al. Impact of polymorphisms in apoptosis‐related genes on the outcome of childhood acute lymphoblastic leukaemia , 2018, British journal of haematology.
[14] Annette S. Kim,et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium , 2018, Blood.
[15] S. Méndez-Ferrer,et al. Myeloid malignancies and the microenvironment. , 2017, Blood.
[16] C. Porter. Germ line mutations associated with leukemias. , 2016, Hematology. American Society of Hematology. Education Program.
[17] M. D. Den Boer,et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. , 2016, Blood.
[18] F. Supek,et al. MUFFINN: cancer gene discovery via network analysis of somatic mutation data , 2016, Genome Biology.
[19] Y. Saeys,et al. Computational flow cytometry: helping to make sense of high-dimensional immunology data , 2016, Nature Reviews Immunology.
[20] Donna Neuberg,et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.
[21] T. Aittokallio,et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. , 2015, Blood.
[22] A. Letai,et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. , 2015, Cancer cell.
[23] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[24] Arndt Borkhardt,et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Julia C. Engelmann,et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia , 2013, Leukemia.
[26] C. Pui,et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. , 2012, The New England journal of medicine.
[27] M. Loh,et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[29] E. Cook,et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.